Evaluation of cardiomyopathy

References

Key articles

Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-1816.Full text  Abstract

Gersh BJ, Maron BJ, Bonow RO, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e783-e831.Full text  Abstract

Elliott PM, Anastasakis A, Borger MA, et al; Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35:2733-2779.Full text  Abstract

Nagueh SF, Bierig SM, Budoff MJ, et al; American Society of Echocardiography; American Society of Nuclear Cardiology; Society for Cardiovascular Magnetic Resonance; Society of Cardiovascular Computed Tomography. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2011;24:473-498.Full text  Abstract

O'Mahony C, Jichi F, Pavlou M, et al; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35:2010-2020.Full text  Abstract

Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al; Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12:767-778.Full text  Abstract

British Society of Echocardiography. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Jun 2017 [internet publication].Full text

Reference articles

1. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-1816.Full text  Abstract

2. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996 Mar 1;93(5):841-2.Full text  Abstract

3. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270-276.Full text  Abstract

4. Lipshultz SE, Law YM, Asante-Korang A, et al. Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. Circulation. 2019 Jul 2;140(1):e9-e68.Full text  Abstract

5. Miles C, Fanton Z, Tome M, et al. Inherited cardiomyopathies. BMJ. 2019 May 2;365:l1570.Full text  Abstract

6. Gersh BJ, Maron BJ, Bonow RO, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e783-e831.Full text  Abstract

7. Elliott PM, Anastasakis A, Borger MA, et al; Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35:2733-2779.Full text  Abstract

8. Nagueh SF, Bierig SM, Budoff MJ, et al; American Society of Echocardiography; American Society of Nuclear Cardiology; Society for Cardiovascular Magnetic Resonance; Society of Cardiovascular Computed Tomography. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2011;24:473-498.Full text  Abstract

9. Guazzi M, Adams V, Conraads V, et al. EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2012;126:2261-2674.Full text  Abstract

10. Christiaans I, van Engelen K, van Langen IM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace. 2010;12:313-321. Abstract

11. Garratt CJ, Elliott P, Behr E, et al. Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace. 2010;12:1156-1175.Full text  Abstract

12. O'Mahony C, Tome-Esteban M, Lambiase PD, et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart. 2013;99:534-541. Abstract

13. McKeown PP, Muir AR. Risk assessment in hypertrophic cardiomyopathy: contemporary guidelines hampered by insufficient evidence. Heart. 2013;99:511-513.Full text  Abstract

14. Aquaro GD, Masci P, Formisano F, et al. Usefulness of delayed enhancement by magnetic resonance imaging in hypertrophic cardiomyopathy as a marker of disease and its severity. Am J Cardiol. 2010;105:392-397. Abstract

15. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867-874. Abstract

16. Maron BJ, Maron MS. LGE means better selection of HCM patients for primary prevention implantable defibrillators. JACC Cardiovasc Imaging. 2016 Jul 14 [Epub ahead of print]. Abstract

17. O'Mahony C, Jichi F, Pavlou M, et al; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35:2010-2020.Full text  Abstract

18. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:201-211. Abstract

19. Hoffmann B. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009;4:21.Full text  Abstract

20. Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis. 2008;3:13.Full text  Abstract

21. Schulz JB, Boesch S, Bürk K, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol. 2009;5:222-234. Abstract

22. Towbin JA. Hypertrophic Cardiomyopathy. Pacing Clin Electrophysiol. 2009;32(Suppl 2):S23-S31. Abstract

23. Cheng TO. Hypertrophic cardiomyopathy vs athlete's heart. Int J Cardiol. 2009;131:151-155. Abstract

24. Corrado D, Basso C, Judge DP. Arrhythmogenic Cardiomyopathy. Circ Res. 2017 Sep 15;121(7):784-802.Full text  Abstract

25. Basso C, Corrado D, Marcus FI, et al. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009;373:1289-1300. Abstract

26. Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988 Jan 21;318(3):129-33.Full text  Abstract

27. Rampazzo A. Genetic bases of arrhythmogenic right ventricular Cardiomyopathy. Heart Int. 2006;2(1):17.Full text  Abstract

28. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Br Heart J. 1994;71:215-218.Full text  Abstract

29. Hamid MS, Norman M, Quraishi A, et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol. 2002:40:1445-1450. Abstract

30. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533-1541.Full text  Abstract

31. Corrado D, Basso C, Thiene G. Arrhythmogenic right ventricular cardiomyopathy: diagnosis, prognosis, and treatment. Heart. 2000;83:588-595.Full text  Abstract

32. Singh DP, Patel H. Left Ventricular Non-compaction (LVNC) Cardiomyopathy. In: StatPearls [Internet]. StatPearls Publishing; 2020

33. Kayvanpour E, Sedaghat-Hamedani F, Gi WT, et al. Clinical and genetic insights into non-compaction: a meta-analysis and systematic review on 7598 individuals. Clin Res Cardiol. 2019 Nov;108(11):1297-1308.Full text  Abstract

34. Pantazis AA, Elliott PM. Left ventricular noncompaction. Curr Opin Cardiol. 2009;24:209-213. Abstract

35. Captur G, Nihoyannopoulos P. Left ventricular non-compaction: genetic heterogeneity, diagnosis and clinical course. Int J Cardiol. 2010;140:145-153. Abstract

36. Towbin JA, Bowles NE. Dilated cardiomyopathy: a tale of cytoskeletal proteins and beyond. J Cardiovasc Electrophysiol. 2006;17:919-926. Abstract

37. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37:1850-1858.Full text  Abstract

38. American Heart Association. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: A scientific statement from the American Heart Association. Nov 2016 [internet publication].Full text  Abstract

39. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet 2010;375:752-762. Abstract

40. Malhotra R, Mason PK. Lamin A/C deficiency as a cause of familial dilated cardiomyopathy. Curr Opin Cardiol. 2009;24:203-208. Abstract

41. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11:31-39.Full text  Abstract

42. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med. 1997;336:267-276. Abstract

43. Zangwill S, Hamilton R. Restrictive cardiomyopathy. Pacing Clin Electrophysiol. 2009;32(Suppl 2):S41-S43. Abstract

44. Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360:1526-1538. Abstract

45. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease. Circulation. 2007;116:2216-2233.Full text  Abstract

46. Akashi YJ, Goldstein DS, Barbaro G, et al. Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. Circulation. 2008;118:2574-2762.Full text  Abstract

47. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008;155:408-417. Abstract

48. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al; Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12:767-778.Full text  Abstract

49. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016 Sep;18(9):1096-105.Full text  Abstract

50. Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100:302-304. Abstract

51. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation. 2005;111:2050-2055.Full text  Abstract

52. Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009;15:645-650. Abstract

53. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709-15. Abstract

54. Calò L, De Ruvo E, Sette A, et al. Tachycardia-induced cardiomyopathy: mechanisms of heart failure and clinical implications. J Cardiovasc Med. 2007;8:138-143. Abstract

55. Maredia N, Ray SG. Cardiac amyloidosis. Clin Med. 2005;5:504-509. Abstract

56. Lubitz SA, Goldbarg SH, Mehta D. Sudden cardiac death in infiltrative cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hemachromatosis. Prog Cardiovasc Dis. 2008;51:58-73. Abstract

57. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021 Apr 21;42(16):1554-68.Full text  Abstract

58. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-Evidence base and standardized methods of imaging. Circ Cardiovasc Imaging. 2021 Jul;14(7):e000029.Full text  Abstract

59. Guertl B, Noehammer C, Hoefler G. Metabolic cardiomyopathies. Int J Exp Pathol. 2000;81:349-372. Abstract

60. Lubitz SA, Goldbarg SH, Mehta D. Sudden cardiac death in infiltrative cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hemachromatosis. Prog Cardiovasc Dis. 2008;51:58-73. Abstract

61. Bristow MR, Mason JW, Billingham ME, et al. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978;88:168-175. Abstract

62. Guglin M, Hartlage G, Reynolds C, et al. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail. 2009;15:651-657. Abstract

63. Fernández-Solà J, Fatjó F, Sacanella E, et al. Evidence of apoptosis in alcoholic cardiomyopathy. Hum Pathol. 2006;37:1100-1110. Abstract

64. Alexander CS. Cobalt-beer cardiomyopathy. A clinical and pathologic study of twenty-eight cases. Am J Med. 1972;53:395-417. Abstract

65. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol. 2006;48:1548-1551. Abstract

66. Akbarian M, Yankopoulos NA, Abelmann WH. Hemodynamic studies in beriberi heart disease. Am J Med. 1966;41:197-212. Abstract

67. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J. 2009;157:9-21. Abstract

68. Zheng ZJ, Croft JB, Giles WH, et al. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104:2158-2163.Full text  Abstract

69. Corrado D, Basso C, Schiavon M, et al. Screening for hypertrophic cardiomyopathy in young athletes. New Engl J Med. 1998;339:364-369.Full text  Abstract

70. Wisten A, Andersson S, Forsberg H, et al. Sudden cardiac death in the young in Sweden: electrocardiogram in relation to forensic diagnosis. J Intern Med. 2004;255:213-220.Full text  Abstract

71. Doolan A, Langlois N, Semsarian C. Causes of sudden cardiac death in young Australians. Med J Aust. 2004 Feb 2;180(3):110-2.Full text  Abstract

72. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease. Circulation. 2007;116:2216-2233.Full text  Abstract

73. Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996;312:222.Full text  Abstract

74. British Society of Echocardiography. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Jun 2017 [internet publication].Full text

75. Schwefer M, Aschenbach R, Heidemann J, et al. Constrictive pericarditis, still a diagnostic challenge: comprehensive review of clinical management. Eur J Cardiothorac Surg. 2009;36:502-510. Abstract

76. Hershberger RE, Givertz MM, Ho CY, et al. Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. J Card Fail. 2018 May;24(5):281-302.Full text  Abstract

77. Finsterer J. Mitochondriopathies. Eur J Neurol 2004;11:163-186. Abstract

78. Braunwald E, Fauci AS, Kasper D, et al, eds. Harrison's principles of internal medicine. New York, NY: McGraw-Hill; 2001:1411.

79. Nunoda S, Genda A, Sekiguchi M, et al. Left ventricular endomyocardial biopsy findings in patients with essential hypertension and hypertrophic cardiomyopathy with special reference to the incidence of bizarre myocardial hypertrophy with disorganization and biopsy score. Heart Vessels. 1985;1:170-175. Abstract

80. Takemura G, Takatsu Y, Fujiwara H. Luminal narrowing of coronary capillaries in human hypertrophic hearts: an ultrastructural morphometrical study using endomyocardial biopsy specimens. Heart. 1998;79:78-85.Full text  Abstract

81. Blomström-Lundqvist C, Selin K, Jonsson R, et al. Cardioangiographic findings in patients with arrhythmogenic right ventricular dysplasia. Br Heart J. 1988;59:556-563.Full text  Abstract

82. Lehnart SE, Ackerman MJ, Benson DW Jr, et al. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation. 2007;116:2325-2345. [Erratum in: Circulation. 2008;118:e132.]Full text  Abstract

83. Wolf CM, Berul CI. Inherited conduction system abnormalities: one group of diseases, many genes. J Cardiovasc Electrophysiol. 2006;17:446-455. Abstract

84. Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009 Mar;55(3):499-504.Full text  Abstract

85. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016 Jun 14;133(24):2404-12.Full text  Abstract

86. O'Mahony C, Elliott P. Anderson-Fabry disease and the heart. Prog Cardiovasc Dis. 2010;52:326-335. Abstract

87. Pieroni M, Chimenti C, De Cobelli F, et al. Fabry's disease cardiomyopathy. J Am Coll Cardiol. 2006;47:1663-1671. Abstract

88. Kounas S, Demetrescu C, Pantazis AA, et al. The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;51:2058-2061. Abstract

89. Saltiel E, McGuire W. Doxorubicin (adriamycin) cardiomyopathy: a critical review. West J Med. 1983;139:332-341.Full text  Abstract

90. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Int Med. 1996;125:47-58. Abstract

91. Colao A. 5 long-term acromegaly and associated cardiovascular complications: a case-based review. Best Pract Res Clin Endocrinol Metab. 2009;23(Suppl 1):S31-38. Abstract

92. van der Burgt I. Noonan syndrome. Orphanet J Rare Dis. 2007;2:4.Full text  Abstract

93. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305-1323.Full text  Abstract

Use of this content is subject to our disclaimer